Ischemic Stroke Market
Ischemic Stroke Market Summary
As per MRFR analysis, the Ischemic Stroke Market Size was estimated at 4918.33 USD Million in 2024. The Ischemic Stroke industry is projected to grow from 5269.11 in 2025 to 10493.74 by 2035, exhibiting a compound annual growth rate (CAGR) of 7.13% during the forecast period 2025 - 2035.
Key Market Trends & Highlights
The Ischemic Stroke Market is poised for substantial growth driven by technological advancements and increasing healthcare expenditure.
- Technological advancements in treatment are reshaping the landscape of ischemic stroke management.
- North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector.
- Thrombotic stroke represents the largest segment, whereas embolic stroke is witnessing the fastest growth.
- Rising incidence of ischemic stroke and advancements in medical technology are key drivers propelling market expansion.
Market Size & Forecast
| 2024 Market Size | 4918.33 (USD Million) |
| 2035 Market Size | 10493.74 (USD Million) |
| CAGR (2025 - 2035) | 7.13% |
Major Players
Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Genentech (US), Roche (CH), AstraZeneca (GB), Sanofi (FR), Pfizer (US), Novartis (CH), Johnson & Johnson (US)
Ischemic Stroke Market Trends
The Ischemic Stroke Market is currently experiencing a dynamic evolution, driven by advancements in medical technology and an increasing understanding of stroke pathophysiology. A comprehensive analysis of ischemic stroke market trends reveals that the growing prevalence of risk factors such as hypertension, diabetes, and obesity is significantly propelling demand for innovative treatment options. The growing prevalence of risk factors such as hypertension, diabetes, and obesity appears to be propelling demand for innovative treatment options. Furthermore, the emphasis on early diagnosis and intervention suggests a shift towards more proactive healthcare strategies. Current ischemic stroke surgery market trends indicate a significant pivot toward minimally invasive endovascular procedures, which are increasingly favored for their ability to reduce recovery times and improve survival rates in acute cases. This trend is likely to enhance patient outcomes and reduce long-term healthcare costs, thereby attracting investment in research and development. A significant driver of this expansion is the rapid evolution of the acute ischemic stroke diagnosis market, which is benefiting from high-precision imaging and automated AI-driven screening tools that reduce door-to-needle time.
A significant driver of this expansion is the diversifying acute ischemic stroke therapeutics market, which is evolving to include high-efficacy neuroprotective agents and next-generation thrombolytics. In addition, the rise of telemedicine and digital health solutions is transforming the landscape of stroke management. These technologies facilitate remote monitoring and timely access to specialists, which may improve patient care and streamline treatment protocols. As healthcare systems adapt to these changes, the Ischemic Stroke Market is poised for substantial growth, with a focus on personalized medicine and tailored therapeutic approaches. The integration of artificial intelligence and machine learning into diagnostic tools could further refine treatment pathways, indicating a promising future for stakeholders in this sector.
Technological Advancements in Treatment
The Ischemic Stroke Market is witnessing a surge in innovative treatment modalities, including mechanical thrombectomy and novel thrombolytic agents. These advancements are likely to enhance the efficacy of interventions, leading to improved patient outcomes. As research continues to unveil new therapeutic targets, the ischemic stroke market may see a diversification of treatment options that cater to varying patient needs.
Focus on Preventive Care
There is a growing emphasis on preventive measures within the Ischemic Stroke Market, as healthcare systems recognize the importance of addressing risk factors early. Initiatives aimed at educating patients about lifestyle changes and risk management strategies are becoming more prevalent. This proactive approach may lead to a reduction in stroke incidence and a shift in market dynamics.
Integration of Digital Health Solutions
The incorporation of digital health technologies is transforming the Ischemic Stroke Market by enabling remote patient monitoring and telehealth services. These solutions facilitate timely interventions and enhance patient engagement in their care. As digital health continues to evolve, it is likely to play a crucial role in shaping future treatment landscapes.
Ischemic Stroke Market Drivers
Growing Geriatric Population
The increasing geriatric population worldwide is a crucial driver of the Global Ischemic Stroke Market Industry. Older adults are at a higher risk of experiencing ischemic strokes due to age-related factors such as vascular changes and comorbidities. As the global population ages, the demand for stroke prevention and treatment services is anticipated to rise. This demographic shift is projected to influence market dynamics significantly, with the Global Ischemic Stroke Market expected to witness a compound annual growth rate of 7.13% from 2025 to 2035. The implications of this trend are profound, as healthcare systems must adapt to meet the needs of an aging population.
Increased Awareness and Education
Growing awareness regarding the symptoms and risk factors associated with ischemic stroke is driving the Global Ischemic Stroke Market Industry. Public health campaigns and educational initiatives have been instrumental in informing individuals about the importance of early recognition and intervention. This heightened awareness encourages individuals to seek medical attention promptly, thereby increasing the demand for diagnostic and therapeutic services. As a result, healthcare systems are likely to allocate more resources towards stroke management, further propelling market growth. The emphasis on education and awareness is expected to play a crucial role in shaping the future landscape of the Global Ischemic Stroke Market.
Advancements in Medical Technology
Technological innovations in medical devices and treatment methodologies are significantly influencing the Global Ischemic Stroke Market Industry. The development of advanced imaging techniques, such as CT and MRI, enhances the ability to diagnose ischemic strokes promptly. Furthermore, the introduction of minimally invasive surgical techniques and novel thrombolytic agents has improved patient outcomes. These advancements not only facilitate timely interventions but also contribute to the overall growth of the market. As the industry adapts to these technological changes, it is likely that the Global Ischemic Stroke Market will continue to expand, potentially reaching 10.5 USD Billion by 2035.
Government Initiatives and Funding
Government initiatives aimed at reducing the incidence of ischemic stroke are pivotal to the Global Ischemic Stroke Market Industry. Various countries are implementing stroke prevention programs and allocating funding for research and development of new treatment options. These initiatives not only enhance healthcare infrastructure but also promote collaboration among stakeholders in the medical community. By investing in public health strategies and supporting clinical trials, governments are likely to foster innovation in stroke care. This commitment to improving health outcomes is expected to contribute significantly to the market's growth trajectory over the coming years.
Rising Prevalence of Ischemic Stroke
The increasing incidence of ischemic stroke globally is a primary driver of the Global Ischemic Stroke Market Industry. According to health statistics, ischemic strokes account for approximately 87% of all strokes, leading to a growing demand for effective treatment options. As populations age and lifestyle-related risk factors such as hypertension and diabetes become more prevalent, the burden of ischemic stroke is expected to rise. This trend is reflected in the market's projected growth, with the Global Ischemic Stroke Market anticipated to reach 4.92 USD Billion in 2024. Such figures underscore the urgent need for innovative therapies and preventive measures.
Market Segment Insights
By Type of Ischemic Stroke: Thrombotic Stroke (Largest) vs. Embolic Stroke (Fastest-Growing)
In the Ischemic Stroke Market, the distribution of market share among types of ischemic stroke reveals that thrombotic strokes represent the largest segment due to their prevalence in the population. They account for a significant portion of total ischemic strokes, often linked to underlying conditions like atherosclerosis. Conversely, embolic strokes, while currently holding a smaller share, are gaining rapid traction as awareness and diagnosis improve, leading to an increase in identified cases. Growth trends in this segment are driven by advancements in diagnostics and treatment options, particularly for embolic strokes, which are becoming increasingly recognized as a critical area for intervention. Factors such as an aging population, rising incidences of cardiac conditions contributing to embolisms, and improved access to healthcare services are fueling the growth of this segment, making embolic strokes the fastest-growing type of ischemic stroke.
Thrombotic Stroke: Dominant vs. Lacunar Stroke: Emerging
Thrombotic strokes are characterized by the formation of a blood clot within a blood vessel of the brain, often associated with atherosclerotic disease. This segment dominates the ischemic stroke market due to its higher incidence rates, driven by lifestyle factors and comorbidities like hypertension and diabetes. In contrast, lacunar strokes, which result from small vessel occlusion within the brain, represent an emerging segment with unique clinical implications. While they constitute a smaller percentage of ischemic strokes, their recognition is growing as the link between small vessel disease and cognitive decline becomes clearer, prompting further research and the development of tailored treatment strategies. As healthcare providers focus on comprehensive stroke management, both segments play vital but distinct roles in shaping the future landscape of ischemic stroke care.
By Treatment Method: Medication (Largest) vs. Surgical Intervention (Fastest-Growing)
The treatment method segment in the Ischemic Stroke Market is delineated primarily into three categories: Medication, Surgical Intervention, and Rehabilitation Therapy. Among these, Medication holds the largest share due to its widespread application in both acute and preventive care for ischemic stroke patients. The availability of various antithrombotic drugs and their efficacy in managing ischemic stroke has solidified their position. In contrast, Surgical Intervention, although smaller in share, is gaining traction as an essential treatment modality, particularly for patients with severe conditions requiring rapid intervention.
Medication (Dominant) vs. Surgical Intervention (Emerging)
Medication remains the dominant treatment method in the Ischemic Stroke Market, characterized by a wide range of antithrombotic therapies that effectively reduce the risks associated with stroke recurrence. Its broad accessibility and effectiveness make it the preferred option for early stage patients. Conversely, Surgical Intervention is emerging as a critical alternative in cases where rapid action is necessary, particularly with advancements in technology such as thrombectomy techniques. This segment is gaining momentum as more healthcare providers adopt surgical options to address complex cases, creating a shift in treatment paradigms that emphasize timely interventions.
By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)
In the Ischemic Stroke Market, patient demographics reveal significant insights into age and gender distribution. The age group segment demonstrates a predominant share, with older adults, especially those aged 65 and above, representing the largest proportion of ischemic stroke patients. This demographic factor heavily influences treatment protocols and healthcare resource allocation. On the other hand, gender breakdown illustrates a growing trend, where females are increasingly being diagnosed, thereby altering clinical approaches and considerations in addressing stroke care.
Age Group (Dominant) vs. Gender (Emerging)
The age group segment is the dominant force in the Ischemic Stroke Market, with older adults being most vulnerable due to age-related health risks. This demographic has specific needs regarding prevention, treatment, and rehabilitation strategies designed to mitigate the effects of ischemic strokes. Conversely, the gender segment is emerging as a critical area of focus, particularly as female representation grows in diagnosis rates. Women's experiences with ischemic strokes may differ due to biological and lifestyle factors, prompting the necessity for tailored therapies that address these unique challenges.
By Severity of Stroke: Mild Stroke (Largest) vs. Severe Stroke (Fastest-Growing)
In the ischemic stroke market, the distribution of severity categories reveals that mild strokes represent the largest share, significantly influencing treatment protocols and resource allocation. Moderate and severe strokes, while smaller in share, are critical to understand due to their implications for long-term care and management. As awareness increases, these segments are becoming more pronounced in clinical settings, influencing both treatment options and patient outcomes. Market growth trends indicate that severe strokes are the fastest-growing category within the ischemic stroke segment. This growth is attributed to an expanding aging population and a rising incidence of risk factors such as hypertension and diabetes. As the healthcare system evolves, innovative therapies and intervention techniques are becoming increasingly available for severe stroke patients, thus propelling this market segment forward.
Mild Stroke (Dominant) vs. Severe Stroke (Emerging)
Mild strokes, often leading to less severe health impacts, dominate the ischemic stroke segment due to their higher prevalence and better prognosis. Patients experiencing mild strokes typically have lower mortality rates and can often recover with minimal intervention, making this segment crucial for preventive care strategies. On the other hand, severe strokes are emerging as a vital area of focus due to their complex treatment needs and the larger long-term care implications. While the mild stroke segment supports early intervention and preventive health measures, the severe stroke segment highlights the need for advanced medical technologies and tailored rehabilitation programs to improve recovery outcomes. As research progresses, treatments for severe strokes are set to grow, enhancing care strategies in this area.
By Healthcare Setting: Hospital (Largest) vs. Home Care (Fastest-Growing)
In the Ischemic Stroke Market, the healthcare setting segment is primarily dominated by hospitals, which maintain the largest share due to their advanced infrastructure and availability of specialized medical staff. Outpatient clinics offer an alternative for less severe cases, while home care is gaining traction as a preferred option for rehabilitation, particularly in post-acute care scenarios. The differentiation in market share highlights the critical role each setting plays in managing ischemic strokes, catering to diverse patient needs and circumstances.
Healthcare Setting: Hospital (Dominant) vs. Home Care (Emerging)
Hospitals remain the dominant setting for ischemic stroke treatment, providing comprehensive care powered by technological advancements, expert staff, and instant access to diagnostic tools and therapies. They are equipped to handle the complexities of stroke cases and post-operative interventions. Conversely, home care is becoming an emerging segment driven by the shift towards patient-centric care, emphasizing comfort and recovery in familiar surroundings. This trend is supported by telehealth advancements and increased focus on personalized rehabilitation programs, catering to patients’ growing preference for receiving care at home.
Regional Insights
North America : Leading Market Innovators
North America is poised to maintain its leadership in the Ischemic Stroke market, holding a significant market share of $2450.0M in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of stroke symptoms, and a rising aging population. Regulatory support for innovative therapies and technologies further fuels demand, making it a hub for research and development in stroke care. The competitive landscape is characterized by major players such as Boehringer Ingelheim, Bristol-Myers Squibb, and Genentech, which are actively involved in developing novel treatments. The U.S. leads the market, supported by robust healthcare policies and funding for stroke research. The presence of key pharmaceutical companies enhances innovation and accessibility, ensuring that patients receive cutting-edge therapies.
Europe : Emerging Regulatory Frameworks
Europe's Ischemic Stroke market is projected to reach $1500.0M by 2025, driven by increasing healthcare investments and a focus on innovative treatment options. The region benefits from a strong regulatory framework that encourages the development of new therapies, addressing the rising incidence of stroke among the aging population. Collaborative efforts among EU member states to improve healthcare access and quality are also significant growth drivers. Leading countries such as Germany, France, and the UK are at the forefront of this market, with a competitive landscape featuring key players like Roche and AstraZeneca. These companies are investing heavily in research and development to introduce advanced therapies. The European market is characterized by a mix of established pharmaceutical firms and emerging biotech companies, fostering a dynamic environment for innovation.
Asia-Pacific : Rapidly Growing Healthcare Sector
The Asia-Pacific region, with a market size of $800.0M, is witnessing rapid growth in the Ischemic Stroke sector. Factors such as increasing urbanization, rising healthcare expenditure, and a growing aging population contribute to the demand for effective stroke management solutions. Governments are implementing policies to improve healthcare access and quality, which is expected to further stimulate market growth in the coming years. Countries like China and India are leading the charge, with significant investments in healthcare infrastructure and technology. The India ischemic stroke surgery market is expanding rapidly as the country invests in specialized neuro-intervention centers and advanced surgical infrastructure to address the rising burden of cardiovascular diseases. The competitive landscape includes both global players and local companies, creating a dynamic environment for innovation. As awareness of stroke prevention and treatment increases, the market is likely to see a surge in demand for advanced therapies and rehabilitation services, enhancing patient outcomes.
Middle East and Africa : Untapped Market Opportunities
The Middle East and Africa region, valued at $168.33M, presents unique challenges and opportunities in the Ischemic Stroke market. The growing prevalence of risk factors such as hypertension and diabetes, coupled with limited access to healthcare services, drives the need for effective stroke management solutions. Furthermore, increasing investments in specialized neurovascular centers are expected to bolster the GCC ischemic stroke surgery market, as member nations prioritize advanced mechanical thrombectomy and surgical intervention capabilities. Governments are increasingly recognizing the importance of addressing these health issues, leading to initiatives aimed at improving healthcare infrastructure and access. Countries like South Africa and the UAE are making strides in enhancing stroke care, with investments in medical technology and training for healthcare professionals. The competitive landscape is evolving, with both international and local players seeking to establish a foothold in this emerging market. As awareness and education around stroke prevention grow, the region is expected to see significant advancements in treatment options and patient care.
Key Players and Competitive Insights
In November Boehringer Ingelheim (DE) announced a strategic partnership with a leading digital health company to integrate AI-driven analytics into its stroke management solutions. This collaboration aims to enhance patient outcomes through personalized treatment plans, indicating a shift towards technology-driven healthcare solutions. Such initiatives not only bolster Boehringer Ingelheim's market position but also reflect a broader trend of integrating digital tools into traditional therapeutic frameworks.
In October Bristol-Myers Squibb (US) launched a new clinical trial for its investigational drug targeting ischemic stroke patients, focusing on a unique mechanism of action that could potentially improve recovery rates. This move underscores the company's commitment to innovation and its proactive approach to addressing unmet medical needs in the stroke population. The trial's outcomes may significantly influence treatment protocols and establish new benchmarks in stroke care.
In September Genentech (US) received regulatory approval for a novel biologic aimed at neuroprotection in ischemic stroke patients. This approval not only enhances Genentech's product portfolio but also positions the company as a leader in the neuroprotective space. The strategic importance of this development lies in its potential to redefine treatment paradigms and improve patient outcomes, thereby solidifying Genentech's competitive edge.
As of December current trends in the Ischemic Stroke Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming pivotal, as companies collaborate to enhance their technological capabilities and expand their market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach market entry and product development, emphasizing the need for agility and responsiveness in a rapidly changing healthcare landscape.
Key Companies in the Ischemic Stroke Market include
Industry Developments
Feb 2022: CERENOVUS, a subsidiary of Johnson & Johnson Medical Devices Company, has introduced EMBOGUARD, a next-generation balloon guide catheter for use in endovascular treatments, particularly those for patients with acute ischemic stroke.
October 2021: With the release of the pRESET 6-50 mechanical thrombectomy device for the treatment of acute large vascular occlusive (LVO) stroke, Phenox expanded its technology portfolio.
Future Outlook
Ischemic Stroke Market Future Outlook
The Ischemic Stroke Market is projected to grow at a 7.13% CAGR from 2025 to 2035, driven by advancements in treatment technologies and increasing patient awareness.
New opportunities lie in:
- Development of telehealth platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of rehabilitation services focusing on personalized care
By 2035, the Ischemic Stroke Market is expected to achieve substantial growth and innovation.
Market Segmentation
Ischemic Stroke Market Risk Factors Outlook
- Hypertension
- Diabetes
- Hyperlipidemia
- Smoking
- Obesity
Ischemic Stroke Market Treatment Method Outlook
- Medication
- Surgical Intervention
- Rehabilitation Therapy
Ischemic Stroke Market Patient Demographics Outlook
- Age Group
- Gender
- Ethnicity
Ischemic Stroke Market Type of Ischemic Stroke Outlook
- Thrombotic Stroke
- Embolic Stroke
- Lacunar Stroke
Report Scope
| MARKET SIZE 2024 | 4918.33(USD Million) |
| MARKET SIZE 2025 | 5269.11(USD Million) |
| MARKET SIZE 2035 | 10493.74(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.13% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Genentech (US), Roche (CH), AstraZeneca (GB), Sanofi (FR), Pfizer (US), Novartis (CH), Johnson & Johnson (US) |
| Segments Covered | Type of Ischemic Stroke, Treatment Method, Risk Factors, Patient Demographics |
| Key Market Opportunities | Advancements in telemedicine enhance timely intervention in the Ischemic Stroke Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the ischemic stroke market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Market Highlights
FAQs
What is the current valuation of the Ischemic Stroke Market as of 2024?
The Ischemic Stroke Market was valued at approximately 4918.33 USD Million in 2024.
What is the projected market size for the Ischemic Stroke Market in 2035?
The market is expected to reach a valuation of around 10493.74 USD Million by 2035.
What is the expected CAGR for the Ischemic Stroke Market during the forecast period 2025 - 2035?
The anticipated CAGR for the Ischemic Stroke Market during the forecast period is 7.13%.
Which companies are considered key players in the Ischemic Stroke Market?
How is the Ischemic Stroke Market segmented by type of stroke?
The market segments by type of ischemic stroke include Thrombotic Stroke, Embolic Stroke, and Lacunar Stroke, with valuations ranging from 2000.0 to 4500.0 USD Million for Thrombotic Stroke.
What are the treatment methods contributing to the Ischemic Stroke Market?
The market segments by treatment method include Medication, Surgical Intervention, and Rehabilitation Therapy, with Medication valued between 2000.0 and 4500.0 USD Million.
How does patient demographics influence the Ischemic Stroke Market?
What is the market segmentation based on the severity of stroke?
What healthcare settings are included in the Ischemic Stroke Market?
What trends are expected to shape the Ischemic Stroke Market in the coming years?
Research Approach
Secondary Research
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed neurological journals, stroke-specific clinical publications, and authoritative neurovascular health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA), Centers for Disease Control and Prevention (CDC) Stroke Statistics Division, World Health Organization (WHO) Global Stroke Observatory, World Stroke Organization (WSO) Global Stroke Fact Sheet, National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS), American Heart Association/American Stroke Association (AHA/ASA) Guidelines Portal, Society of Vascular and Interventional Neurology (SVIN), Congress of Neurological Surgeons (CNS), European Stroke Organisation (ESO), National Center for Health Statistics (NCHS) Stroke Hospitalization Data, EU Eurostat Healthcare Database, OECD Health Statistics, and national stroke registry reports from key markets (China National Stroke Registry, UK Sentinel Stroke National Audit Programme, Get With The Guidelines-Stroke US database).
The following sources were employed to gather stroke incidence statistics, regulatory approval data for neurovascular devices, clinical safety and efficacy studies for thrombolytic therapies, demographic trends in cardiovascular disease, and competitive landscape analysis for mechanical thrombectomy devices, AI-powered stroke imaging software, and acute stroke diagnostic modalities.
Primary Research
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Neurovascular Business Units, regulatory affairs chiefs, and commercial directors from mechanical thrombectomy device manufacturers, thrombolytic pharmaceutical companies, diagnostic imaging OEMs, and AI stroke detection software developers. Interventional neurologists, neurosurgeons, stroke center medical directors, emergency medicine department heads, neuroradiologists, and procurement leads from comprehensive stroke centers, primary stroke centers, academic medical centers, and diagnostic imaging facilities comprised demand-side sources. Market segmentation between ischemic and hemorrhagic stroke indications was validated through primary research. Neurovascular product pipeline timelines were confirmed, and clinical adoption patterns of stent retrievers vs. aspiration systems, AI imaging software pricing models, and reimbursement dynamics for mechanical thrombectomy procedures were gathered.
Primary Respondent Breakdown:
• By Designation: C-level Primaries (40%), Director Level (30%), Others (30%)
• By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Market Size Estimation
Revenue mapping and procedure volume analysis were implemented to determine global market valuation. The methodology comprised the following:
• The identification of 45+ key manufacturers in the regions of North America, Europe, Asia-Pacific, and Latin America for neurovascular interventions (thrombectomy devices), stroke diagnostics (CT/MRI/ultrasound), thrombolytic pharmaceuticals, and AI-enabled stroke software.
• Product mapping for mechanical thrombectomy (stent retrievers, aspiration catheters, combination systems), thrombolytic therapy (tissue plasminogen activator, antiplatelet agents), diagnostic imaging (non-contrast CT, CT angiography, MRI diffusion-weighted imaging), and AI decision-support software categories
• Examination of the annual revenues that have been reported and modeled for neurovascular stroke portfolios and acute stroke diagnostic instruments
• In 2024, the coverage of manufacturers will account for 65-70% of the global market share.
• Derive segment-specific valuations for ischemic stroke diagnosis, treatment, and post-acute monitoring through extrapolation using bottom-up (stroke procedure volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches.
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
